Kisunla is the first amyloid plaque-targeting therapy that allows for stopping treatment upon plaque removal, company says.
FDA Approves Lilly’s Kisunla for the Treatment of Early Symptomatic Alzheimer’s Disease
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours